It has been reported that anti-phospholipid antibodies are detected in some patients with idiopathic thrombocytopenic purpura (ITP). To study the significance of determination of antiphospholipid antibodies in patients with ITP, clinical and laboratory findings were compared between patients whose sera were positive for these antibodies (Group A) and non-positive patients (Group B). Anti-cardiolipin antibody (aCL) was determined by enzyme-linked immunosorbent assay and lupus anticoagulant (LA) was determined by activated partial thromboplastin time (aPTT) and thromboplastin time inhibition test. Seven out of27 cases ofITP belonged to Group A and 3 of the 7 were confirmed to have anti-phospholipid antibody syndrome (APS). There was a tendency for habitual abortion, and thrombosis, megakaryocytes in the bone marrow and plateletassociated IgG (PAIgG)-positive cells were more frequent in Group A than in Group B. However, it was difficult to discriminate APSfrom ITP alone, whenthere were no symptomsor signs ofAPS. Therefore, measurement of anti-phospholipid antibodies in ITP was thought to be useful for the differential diagnosis of APS and subsequently for the prevention of thrombosis. (Internal Medicine 36: 882-885, 1997) 
Introduction
Idiopathic thrombocytopenic purpura (ITP) is characterized by thrombocytopenia and is divided into two types; acute type which occurs in children and is characterized by antecedent viral infection, and chronic type which occurs in adults, thought to be associated with immunological disorders and characterized by positive test for platelet associated immunoglobulin G (PAIgG) . Thrombocytopenia occurs also in anti-phospholipid antibody syndrome (APS), which is characterized by thrombosis, habitual abortion and a positive test for anti-phospholipid antibodies (1, 2) . Anti-phospholipid antibodies are thought to bind to phospholipids on the surface of the platelet and might be recognized as PAIgG. It may be, therefore, difficult to distinguish APS from ITP, if there are no symptoms of thrombosis, abortion or serum anti-phospholipid antibodies detectable. Recently, it has been reported that anti-cardiolipin antibody (aCL) was detected in the sera from some patients with ITP (3, 4) , but complication of APShas rarely been reported. To study the significance of determination of anti-phospholipid antibodies in patients with ITP, we compared the clinical findings between patients with ITP whose sera were positive for antiphospholipid antibodies and those which were not positive.
Materials and Methods

Patients
Twenty-seven patients (male, 5; female, 22; median age, 40) who met the following criteria for ITP were used; 1. bleeding tendency, 2. a) low platelet count (<10xl04/|Ul), normal red blood cells (RBC) and white blood cells (WBC) in number and shape in the peripheral blood, b) normal or increased number of megakaryocytes and normal number of erythroblasts and granulocytes and shape in the bone marrow, c) positive test for PAIgG. Twenty-four patients were newly diagnosed in this clinic and the other 3 patients were diagnosed and treated elsewhere for three years or more before admission to our hospital because of recurrence of thrombocytopenia. After diagnosis was made, all patients were administered prednisolone (40-60 mg/day); they were not given any immunosuppressive agents during this study.
Methods
APS was diagnosed when the patient had the following 2 items ; 1. Arterial/venous thrombosis , habitual abortion or thrombocytopenia. 2. Positivity for anti-phospholipid antibodies.
Anti-phospholipid antibodies were regarded as positive if the serum was positive for either aCLor LA, or biologically falsepositive for syphilis (BFP). Patients were divided into 2 groups;
Group A included 7 patients with a prolonged activated partial thromboplastin time (aPTT) and anti-phospholipid antibodies. Three patients in Group A were diagnosed later to have APS because they had cerebral thrombosis or habitual abortion. The other 4 patients did not have any symptomsor signs of APS. Group B included those who were not complicated by APS, prolongation of aPTT, LA, aCL nor BFP. Between these two groups, the clinical and laboratory findings including PAIgG, LA, aCL, the bone marrow feature and the period from the beginning of the treatment to the time of recovery of the platelet count (>10xl04/jLim) were compared. Laboratory data were determined within a one-weekinterval from bone marrow aspiration. PAIgG was determined by flowcytometry. Briefly, platelet rich plasma was treated with fluorescein isothiocyanate (FITC) -conjugated anti-human immunoglobulin G (IgG) F(ab' )2 (Silenus Laboratory, Hawthorn, Australia), washed with phosphate buffered saline (pH 7.4) and observed with Cytoron (Ortho Diagnostic Systems, Tokyo). The cut off level for PAIgGwas determined from preliminary experiments using age-and sex-matched normal healthy donors (5). When 10% or moreof the platelets were positively stained, the sample was regarded as PAIgGpositive. LA was detected by thromboplastin time inhibition test. Whenthe coagulation time of the plasma in the presence of 0. 1 % thromboplastin (Simplastin, Organon Teknika Corporation, Tokyo) was over 1.3 times control plasma, the sample was regarded as LA positive. The p2 GPI-dependent aCL was determined using an enzyme-linked immunosorbent assay (ELISA) kit (Yamasa, Tokyo), in which a cardiolipinfixed microplate treated with purified human (J2 GPI was used. The cut off level was 3.5 units/ml according to manufacturer's instructions. Serumanti-nuclear antibody was detected by a kit (Fluoro HEPANAtest, MBL, Nagoya) using Hep-2 cells derived from human nasopharyngeal cancer, and represented as (-) or (+). Anti-DNA antibody (aDNA) and anti-double-stranded DNAantibody (anti-dsDNA) was determined by a passive hemagglutination kit (DNA-HAtest, Kyowa Ltd., Tokyo) and a radioimmunoassay kit (ADNAkit II, Ortho Clinical Diagnostics Ltd., Tokyo) using double-stranded synthetic DNA,respectively. ADNAwas represented as (-) to (3+). Anti-dsDNA was determined according to international units; samples of over 10 units/ml were regarded as positive. Determination of LA, aCLand aPTTwas repeated two times or more (one was done at diagnosis and others were done 2-3 weeksafter the initial determination). Statistical difference between the two groups was tested by using Fisher' s exact method and Student' s t-test.
Results
Profile of the patients All patients studied were diagnosed as having chronic type ITP. Profile of the patients is shown in Table 1 . The male/female ratio and the age was not different between the two groups.
Frequency of habitual abortion, thrombosis, positive tests for LA and aCL had a tendency to be higher in Group A than in Group B, although the difference between the two groups did not reach significance due to the lack of the numberof cases.
The mean titer ofaCL in Group A was 5.0 ± 4.1 units/ml (SD). APTTwas elongated in Group A as compared with Group B (p<0.05).
The initial dose of prednisolone and the period necessary for the recovery of the platelet count was not different between the two groups. The changes of LA, aCL and aPTT werevariable after the treatment and there was no relationship between the platelet count and aCL titer (data not shown). Within Group A, there was no remarkable difference in the platelet count and the bleeding tendency between the 3 patients whowere diagnosed later as having APSand those with only positive anti-phospholipid antibodies (data not shown).
Piatelet count and bone marrow
As shown in Table 2 , the platelet count in the peripheral blood did not significantly differ between the 2 groups, but nucleated cell and megakaryocyte count in the bone marrow were higher in group A than in group B (p<0.05, each).
Frequency of autoantibodies
The percentage ofPAIgG-positive cells was higher in Group A than in Group B, while all patients studied were positive for PAIgG (p<0.05, each) ( Table 3 ). The positivity rates ofaDNA, anti-nuclear antibody (ANA), direct and indirect Coombs' test were also higher in Group A than in Group B, although the difference did not reach significance (p<0.0 1 , each). However, serum anti-dsDNAwas not detected and no remarkable signs and symptomsof systemic autoimmunediseases such as systemic lupus erythematosuswereobservedthroughoutthe clinical course in all patients with or without aDNAor ANA.
Discussion
Several investigators have detected autoantibodies reactive to platelet-associated glycoproteins (GP' s) in the sera from the patients with ITP, some of which are detected as PAIgG (6-9). On the other hand, some patients with APSmight be diagnosed as having ITP, since antibodies to phospholipids on the platelet could be also recognized as PAIgG. Stasi et al (9) have reported that 46.3% of the patients with ITP were positive for either LA or aCL. We also detected LA in 7.4% and aCL in 18.5% of the ITP patients. The difference in the frequency might be due to the sensitivity of the assays. The platelet count and the period of its recovery were not different statistically between the two groups and there was no relationship between the platelet count and the aCLtiter. These findings were similar to theirreport in that there was no difference in the clinical findings and the response to the treatment based on the presence or absence of anti-phospholipid antibodies. Nucleated cells and megakaryocytes in the bone marrow tended to be increased in number in Group A and not in Group B. In addition, PAIgG-positive platelets were more frequent in Group A than in Group B. These findings in Group A were rather characteristic of conventional ITP. Therefore, it was difficult to discriminate the two groups only by PAIgGand bone marrow findings. In this study, autoantibodies such as aDNAor Coombs' test were detected more frequently in Group A than in Group B.
Taken together with previous reports that various autoantibodies are detected in APS (10-13), PAIgG in Group A mightbe apart of the numerous autoantibodies in APS, and the existence of these autoantibodies might serve as a means of discriminating APSor APS-associated cases from the cases with ITP alone. Wecould not find any difference in the platelet count and the bleeding tendency by the presence or absence of APSwithin Group A. In APS, however, it is known that severe thrombocytopenia and bleeding tendency like ITP are rare, and that rather hypercoagulability is present. Therefore, comparison between the cases with APS and those with only positive test for antiphospholipid antibodies should be done using more cases in the future. Further, whether or not complication due to the presence of anti-phospholipid antibodies leads to manifestation of APS should be elucidated. These data suggest that a large number of patients with APS or a positive test for anti-phospholipid antibodies may be included in those diagnosed as ITP. Although it is not clear whether anti-phospholipid antibodies are associated with thrombocytopenia, detection of these antibodies is thought important for discrimination of APS from ITP, and subsequently for the prevention of thrombosis.
Conclusion
Serum anti-phospholipid antibodies were determined in patients with ITP. Detection of these antibodies was thought useful for discrimination of APS from ITP, and subsequently for the prevention of thrombosis. 
